Immunocytochemistry for hTERT, CD56 and HBME-1 in thyroid tumors
Not Applicable
- Conditions
- Health Condition 1: C73- Malignant neoplasm of thyroid gland
- Registration Number
- CTRI/2020/06/025597
- Lead Sponsor
- Maulana Azad Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.New cases of thyroid masses reported as Bethesda III-VI.
2.Cases of thyroid masses reported as definitely Benign lesions (Bethesda II).
Exclusion Criteria
1.Cases of thyroid masses who have received previous radio or chemo therapy.
2.Cases of thyroid masses who have received previous treatment for hyper- or hypothyroidism.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cytological expressions of hTERT, CD56 and HBME-1 in thyroid lesions.Timepoint: Single Time.
- Secondary Outcome Measures
Name Time Method Based on the expression of these markers differentiating thyroid lesions into various Bethesda categories and correlating with histopathology.Timepoint: Single Time.